A clinical trial about effects of prebiotic and probiotic supplementation on weight loss, psychological profile and metabolic parameters in obese subjects

Abstract Introduction The management of obesity is difficult with many failures of lifestyle measures, hence the need to broaden the range of treatments prescribed. The aim of our work was to study the influence of pre and probiotics on weight loss psychological profile and metabolic parameters in obese patients. Methods It is a clinical trial involving 45 obese patients, recruited from the Obesity Unit of the National Institute of Nutrition between March and August 2022 divided into three groups: diet only (low‐carbohydrate and reduced energy diet), prebiotics (30 g of carob/day) and probiotics (one tablet containing Bifidobacterium longum, Lactobacillus helveticus, Lactococcus lactis, Streptococcus thermophilus/day). The three groups were matched for age, sex and BMI. Patients were seen after 1 month from the intervention. Anthropometric measures, biological parameters, dietary survey and psychological scores were performed. Results The average age of our population was 48.73 ± 7.7 years, with a female predominance. All three groups showed a significant decrease in weight, BMI and waist circumference with p <.05. Only the prebiotic and probiotic group showed a significant decrease in fat mass (p =.001) and a significant increase in muscle strength with p =.008 and.004, but the differences were not significant between the three groups. Our results showed also a significant decrease in insulinemia and HOMA‐IR in the prebiotic group compared to the diet‐alone group (p =.03; p =.012) and the probiotic group showed a significant decrease in fasting blood glucose compared to the diet alone group (p =.02). A significant improvement in sleep quality was noted in the prebiotic group (p =.02), with a significant decrease in depression, anxiety and stress in all three groups. Conclusions The prescription of prebiotics and probiotics with the lifestyle measures seems interesting for the management of obesity especially if it is sarcopenic, in addition to the improvement of metabolic parameters and obesity‐related psychiatric disorders.

Abstract licence: CC BY

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.